Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model

International Journal of Gynecological Cancer

Volumn 18, Issue 2, 2008, Pages 329-338

  Wu, W ^a   Celestino, J ^a   Milam, M R ^a   Schmeler, K M ^a   Broaddus, R R ^a   Ellenson, L H ^b   Lu, K H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Animal model; Endometrial hyperplasia; PTEN; Rosiglitazone

Indexed keywords

BROXURIDINE; CELL PROTEIN; DNA FRAGMENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE MUTATION; GROWTH INHIBITION; HETEROZYGOSITY; MOUSE; NICK END LABELING; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; ENDOMETRIAL HYPERPLASIA; FEMALE; HETEROZYGOTE; MICE; MUTATION; PPAR GAMMA; PTEN PHOSPHOHYDROLASE; THIAZOLIDINEDIONES;

EID: 40549090280     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01002.x     Document Type: Article

References (31)

1. Mutter GL, Ince TA, Baak JP et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001 61 : 4311 4.
2. Podsypanina K, Ellenson LH, Nemes A et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999 96 : 1563 8.
3. Stambolic V, Tsao MS, Macpherson D et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 2000 60 : 3605 11.
4. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990 347 : 645 50.
5. Kliewer SA, Umesono K, Noonan DJ et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992 358 : 771 4.
6. Clay CE, Monjazeb A, Thorburn J et al. 15-Deoxy-delta12, 14-prostaglandin J2-induced apoptosis does not require PPAR-gamma in breast cancer cells. J Lipid Res 2002 43 : 1818 28.
7. Palakurthi SS, Aktas H, Grubissich LM et al. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001 61 : 6213 8.
8. Suh N, Wang Y, Williams CR et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999 59 : 5671 3.
9. Yin Y, Russell RG, Dettin LE et al. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 2005 65 : 3950 7.
10. Lu J, Imamura K, Nomura S et al. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res 2005 65 : 4769 74.
11. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004 5 : 419 29.
12. Patel L, Pass I, Coxon P et al. Tumor suppressor and anti-inflammatory actions of PPAR-gamma agonists are mediated via upregulation of PTEN. Curr Biol 2001 11 : 764 8.
13. Teresi RE, Shaiu CW, Chen CS et al. Increased PTEN expression due to transcriptional activation of PPAR-gamma by Lovastatin and Rosiglitazone. Int J Cancer 2006 118 : 2390 8.
14. Wang H, Douglas W, Lia M et al. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Am J Pathol 2002 160 : 1481 6.
15. Mehta RG, Williamson E, Patel MK et al. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000 92 : 418 23.
16. Elstner E, Muller C, Koshizuka K et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998 95 : 8806 11.
17. Sarraf P, Mueller E, Jones D et al. Differentiation and reversal of malignant changes in colon cancer through PPAR-gamma. Nat Med 1998 4 : 1046 52.
18. Osawa E, Nakajima A, Wada K et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterol 2003 124 : 361 7.
19. Mueller E, Smith M, Sarraf P et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000 97 : 10990 5.
20. Saez E, Tontonoz P, Nelson MC et al. Activators of the nuclear receptor PPAR-gamma enhance colon polyp formation. Nat Med 1998 4 : 1058 61.
21. Lefebvre AM, Chen I, Desreumaux P et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998 4 : 1053 7.
22. Mukherjee R, Davies PJ, Crombie DL et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997 386 : 407 10.
23. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000 40 : 491 518.
24. Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 2000 32 : 187 204.
25. Kodera Y, Takeyama K, Murayama A et al. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J Biolumin Chemilumin 2000 275 : 33201 4.
26. Yang W, Rachez C, Freedman LP. Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. Mol Cell Biol 2000 20 : 8008 17.
27. Yao CJ, Lai GM, Chan CF et al. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006 118 : 773 9.
28. Chen A, Xu J. Activation of PPAR {gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 2005 288 : G447 56.
29. Huang JW, Shiau CW, Yang YT et al. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 2005 67 : 1342 8.
30. Farrow B, Evers BM. Activation of PPAR-gamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 2003 301 : 50 3.
31. Brinton LA, Berman ML, Mortel R et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 1992 167 : 1317 25.